Login | New Member? Signup Free
ChangeDetect » News

Amgen pleads guilty to improper marketing of anemia drug Aranesp

The Thousand Oaks biotech giant also agrees to pay $762 million to resolve related complaints from whistle-blowers. Biotech giant Amgen Inc. pleaded guilty in federal court to improper marketing of its anemia drug Aranesp and has agreed to pay $762 million in criminal fines and civil settlements to resolve complaints from company whistle-blowers.

Tags: , , , , , , , , , ,